Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology

Sánchez, Manuel Anguita; Conde, Almudena Castro; Cordero, Alberto; Marimón, Xavier García-Moll; Doblas, Juan José Gómez; González-Juanàtey, José Ramón; Corbi, Rosa María Lidón; López‐Sendón, José; Prieto, José M. Mostaza; Padial, Luis Rodrı́guez

doi:10.1016/j.rec.2016.05.033

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lowering of LDL-C level is fundamental to risk reduction in high-risk patients, including those with ASCVD or diabetes, yet lipid management in high-risk patients remains challenging in Canada and beyond. 11 , 12 The 2021 CCS lipid guidelines included stronger recommendations for combination LDL-C-lowering therapies in patients with ASCVD, based on clinical trials that were published after the 2016 CCS lipid guidelines, including randomized trials and subgroup analyses of PCSK9 inhibitor therapy. 13 , 14 , 15 A previous study assessed specialist knowledge of the 2016 CCS lipid guidelines for ACS patients, but those guidelines offered limited guidance in selecting between ezetimibe and PCSK9 inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients

Taboun¹,

Naik²,

Brown³

et al. 2023

CJC Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients

Taboun¹,

Naik²,

Brown³

et al. 2023

CJC Open

View full text Add to dashboard Cite

“…Investigators were invited to participate and share their results using a simple database designed by the study and investigators from 18 different Spanish hospitals finally agreed to participate; all were included in the public national health system. All patients had to fulfil the indications for reimbursement approved by the Spanish Ministry of Health 16 . The study protocol included the collection of age, sex, classical risk factors, previous cardiovascular disease and lipid‐lowering treatments.…”

Section: Methodsmentioning

confidence: 99%

Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry

Cordero

Olmo

Quiroga

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low‐density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, the effect of other lipid parameters, such as cholesterol remnants or, the so‐called lipid residual risk, is unknown. Methods Multicenter and retrospective registry of patients treated with PCSK9 inhibitors from 14 different hospitals in Spain. Before and on‐treatment lipid parameters were recorded. Residual lipid risk was estimated by (1) cholesterol remnants, (2) triglycerides/HDLc ratio (TG/HDL), (3) total cholesterol/HDLc (TC/HDL) and (4) the triglycerides‐to‐glucose index (TGGi). Results Six hundred fifty‐two patients were analysed, mean age of 60.2 (9.63) years, 24.69% women and mean LDLc before treatment 149.24 (49.86) mg/dl. Median time to second blood determination was 187.5 days. On‐treatment LDLc was 67.46 (45.78) mg/dl, which represented a 55% reduction. Significant reductions were observed for TG/HDL ratio, cholesterol remnants, TC/HDL ratio and TGGi. As consequence, 34.61% patients had LDLc <55 mg/dl and cholesterol remnants <30 mg/dl; additionally, 31.95% had cholesterol remnants <30 mg/dl but LDLc >55 mg/dl. Patients who had levels of cholesterol remnants >30 mg/dl before initiating the treatment with PCSK9 had higher reductions in cholesterol remnants, TG/HDL ratio, TC/HDL and TGGi. By contrast, no reduction differences were observed according to baseline LDLc (< or > the mean), age, gender or obesity. Conclusions This multicenter and retrospective registry of real‐world patients treated with PCSK9 inhibitors demonstrates a positive effect on cholesterol remnants and lipid residual risk beyond LDLc reductions.

show abstract

Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial

Párraga-Martínez

Escobar-Rabadán

Rabanales-Sotos

et al. 2018

Revista Española de Cardiología (English Edition)

View full text Add to dashboard Cite

Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology

Cited by 5 publications

References 18 publications

Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients

Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients

Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry

Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial

Contact Info

Product

Resources

About